You are here

Article Text

Article menu

other Versions

Download PDFPDF
Adverse drug reactions
PRIDE syndrome
  1. Dibyendu Bikash Bhanja1,
  2. Abheek Sil2,
  3. Esther J Punithakumar1,
  4. Avik Panigrahi1,
  5. Avijit Das1,
  6. Surajit Kumar Biswas2
  1. 1Dermatology, Venereology, and Leprosy, RG Kar Medical College and Hospital, Kolkata, India
  2. 2Dermatology, Venereology, and Leprosy, RG Kar Medical College, Kolkata, India
  1. Correspondence to Dibyendu Bikash Bhanja, Department of Dermatology, Venereology, and Leprosy, R G Kar Medical College and Hospital, 1, Khudiram Bose Sarani, Kolkata, West Bengal, India; dibyendubhanja0901{at}gmail.com

http://dx.doi.org/10.1136/postgradmedj-2020-137939

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Epidermal growth factor receptor inhibitors (EGFRIs) are currently used to treat advanced malignancies with definite improvement in the survival and quality of life. Although well tolerated and devoid of severe systemic side-effects, these novel agents have been associated with a constellation of specific dermatologic findings termed as ‘PRIDE’ (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to EGFR inhibitors) complex.1

    A 61-year-old woman, diagnosed with gall bladder carcinoma (postoperative) stage T1N0Mx and on treatment with tablet erlotinib 150 mg daily for the past 5 months, presented with pruritic lesions over the face of 10 days’ duration. She had previously received three cycles of oral capecitabine, which was stopped 2 months ago due to severe hand–foot reaction. Examination revealed multiple discrete follicular inflammatory papules and pustules …

    View Full Text

    Footnotes

    • Statements All the authors consented to publish this manuscript. Informed consent and releases from the parent(s)/guardian(s) and/or the patient were taken.

    • Contributors DBB, AS and EJP contributed to initial patient assessment and follow-up, conception, drafting of manuscript, and final approval of manuscript. AP, AD and SKB contributed to conception, critical revision of content and final approval of manuscript. All authors are in agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

    • Competing interests None declared.

    • Patient consent for publication Consent obtained directly from patient(s).

    • Provenance and peer review Not commissioned; externally peer reviewed.